Ypsomed will establish its first manufacturing facility in the United States. The company has selected Holly Springs in Wake County, North Carolina, as the location and will invest around CHF 200 million in a first phase. This is another milestone in Ypsomed’s global growth strategy, bringing the company closer to its customers and enabling it to serve local markets directly. From end of 2027 onwards, the new site in Holly Springs will supply products for the U.S. market.
The North American manufacturing facility will expand Ypsomed’s production capacity and strengthen its global partnerships. To accelerate its expansion, Ypsomed is buying a building with 15,000 square meters (>160,000 sq ft) with an option for further expansion. The company initially plans to create around 100 new jobs, with the goal of expanding the workforce to about 200 in the coming years as demand increases.
Establishing the new production site in the United States marks an important step in Ypsomed’s global growth strategy. The cooperative approach of the local authorities, the excellent infrastructure, and the proximity to top-tier universities provide ideal conditions for future growth. This environment will allow the company to attract a skilled workforce to further strengthen its position as a leading supplier of self-injection systems worldwide, while contributing to the security of supply for the U.S. healthcare market, said Simon Michel, CEO of Ypsomed.
With more than 650 life sciences operations in North Carolina’s Research Triangle alone, every stage of the biopharmaceutical supply chain is represented from research and product development to device manufacturing, fill/finish, and delivery. Wake County brings together research, talent and community to scale the industry and move ideas to market.
"This announcement brings an expansion in the life science offerings in Holly Springs, diversifying the types of companies located here," said Town of Holly Springs Mayor Sean Mayefskie. "Everyone knows about the global biotech leaders who call Holly Springs home, and Ypsomed will provide needed supplies to contribute to the creation of life-saving medications these companies will produce right here in Holly Springs."
Ypsomed is consistently driving forward its global growth strategy to meet the worldwide increase in demand for injection systems for self-medication and to further strengthen customer proximity. This year, the company opened its first own manufacturing site in Changzhou, China, and launched the expansion of its “Schwerin 2” production facility in Germany. Over the coming years, Ypsomed will invest several hundred million Swiss francs in state-of-the-art infrastructure at this site. Ypsomed is also investing in expanding its production capacities in Switzerland. After modernizing and enlarging its Lochbach production site in Burgdorf in 2023, the company is now taking the next step: around CHF 200 million are being invested in the expansion of the Solothurn site. The corresponding construction and renovation work has already begun.